// App-Quantinova.ai

198 : Adherence to Pangenotypic Glecaprevir/ Pibrentasvir Treatment and SVR12 in HCV‐ infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program

Researchers

Presenter

  • Ashley S. Brown

Principal Investigators

  • Tania M. Welzel

  • Brian Conway

  • Francesco Negro

  • Norbert Brau

  • Jason Grebely

  • Massimo Puoti

  • Henning Kleine

  • David Pugatch

  • Federico J. Mensa

  • Yaozhu J. Chen

  • Yang Lei

  • Eric Lawitz

Medical Centers

  • Imperial College, London, United Kingdom

  • Goethe University, Frankfurt, Germany

  • Vancouver Infectious Diseases Centre, Vancouver, BC, Canada

  • Divisions of Gastroenterology and Hepatology and Clinical Pathology, University Hospital, Geneva, Switzerland

  • James J. Peters VA Medical Center, Bronx, NY

  • Mount Sinai School of Medicine, New York, NY

  • Kirby Institute, UNSW Sydney, Sydney, NSW, Australia

  • Department of Infectious Diseases, Hospital Niguarda Ca'Granda, Milan, Italy

  • AbbVie, Inc., North Chicago, IL

  • Texas Liver Institute, San Antonio, TX

Locations

  • United Kingdom

  • Germany

  • Canada

  • Switzerland

  • United States

  • Australia

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pibrentasvir

  • Glecaprevir

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved